Low B12 status (200300 pg/mL) without obvious symptoms affects up to 40% in Western populations [10]
BPC 157 Rescued NSAID-Cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection Current Pharmaceutical Design BPC-157 counteracted NSAID-induced intestinal damage by stabilizing intestinal permeability, restoring cytoprotective prostaglandin systems, and recovering leaky-gut syndrome pathways
These muscle disabilities were induced by different peripheral causes (e.g., direct muscle, tendon, ligament, and nerve injury [80,81,82,83,84,85,86,87,88,89,90,91], succinylcholine [227], vascular occlusion [228], over-dose of potassium, magnesium or lithium [138,216,229], and tumor cachexia [22])
Gastrointestinal effects nausea, vomiting, diarrhea, and constipation are the most common and can be amplified when two appetite-suppressing compounds are used together
Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption
The mice were fed ad libitum after APAP application
